An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Zhi Hao ^c   Vaziri, Nosratola D ^b   Wei, Feng ^d   Cheng, Xian Long ^d   Bai, Xu ^e   Zhao, Ying Yong ^a,b  

^a NORTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e Waters Technologies Shanghai Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT;

ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; CYTOCHEMISTRY; DISEASE MODEL; FIBROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METABOLOME; PATHOLOGY; PLASMA; RHEUM; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; HISTOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METABOLOME; PLANT EXTRACTS; PLASMA; RATS, SPRAGUE-DAWLEY; RHEUM; TREATMENT OUTCOME;

EID: 84959020373     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22151     Document Type: Article

References (55)

1. Zeisberg, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 21, 1819-1834 (2010).
2. Agarwal, S. K. et al. Chemistry and pharmacology of rhubarb (Rheum species)-A review. J Sci Ind Res. 60, 1-9 (2001).
3. Yin, L. et al. Diuretic activity in rats: the ethanol and aqueous extracts of rhubarb. FASEB J. 28, 657-651 (2014).
4. Chen, H. et al. Urine metabolomics reveals new insights into hyperlipidemia and the therapeutic effect of rhubarb. Anal Methods. 7, 3113-3123 (2015).
5. Mitsuma, T., Terasawa, K., Yokozawa, T. & Oura, H. Rhubarb therapy in patients with chronic renal failure (Part 1). J Med Pharm Soc for Wakan-Yaku. 1, 266-278 (1984).
6. Mitsuma, T., Yokozawa, T., Oura, H. & Terasawa, K. Rhubarb therapy in patients with chronic renal failure (Part 2). Jpn J Nephrol. 29, 195-207 (1987).
7. Li, X. & Wang, H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv. Chronic Kidney Dis. 12, 276-281 (2005).
8. Yokozawa, T. et al. Effect of orally administered rhubarb extract in rats with chronic renal failure. Chem. Pharm. Bull 32, 4506-4513 (1984).
9. Zhao, Y. Y. & Lint, R. C. Metabolomics in nephrotoxicity. Adv. Clin. Chem. 65, 69-89 (2014).
10. Posada-Ayala, M. et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85, 103-111 (2014).
11. Zhao, Y. Y. Metabolomics in chronic kidney disease. Clin. Chim. Acta. 422, 59-69 (2013).
12. Zhao, Y. Y. et al. Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats. J Ethnopharmacol. 148, 403-410 (2013).
13. Reis, A. et al. Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. J Lipid Res. 56, 413-422 (2015).
14. Vaziri, N. D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. Renal Physiol. 290, 262-272 (2006).
15. Vaziri, N. D., Navab, M. & Fogelman, A. M. HDL metabolism and activity in chronic kidney disease. Nat. Rev. Nephrol. 6, 287-296 (2010).
16. Kaysen, G. A. Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney Int. 70, S55-S58 (2006).
17. Tsuruya, K. et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. 233, 260-267 (2014).
18. Watson, A. D. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 47, 2101-2111 (2006).
19. Meikle, P. J., Wong, G., Barlow, C. K. & Kingwell, B. A. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol. Ther. 143, 12-23 (2014).
20. Zhao, Y. Y., Cheng, X. L. & Lin, R. C. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. Int. Rev. Cell Mol. Biol. 313, 1-26 (2014).
21. Chen, H. et al. Metabolomics in dyslipidemia. Adv. Clin. Chem. 66, 101-119 (2014).
22. Hu, C. et al. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B 877, 2836-2846 (2009).
23. Li, M., Yang, L., Bai, Y. & Liu, H. Analytical methods in lipidomics and their applications. Anal. Chem. 86, 161-175 (2014).
24. Zhao, Y. Y. et al. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem. Biol. Interact 220, 181-192 (2014).
25. Miao, H. et al. Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in dietinduced hyperlipidemia. Chem. Biol. Interact 228, 79-87 (2015).
26. Zhao, Y. Y. et al. Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MSE data collection technique. Biomarkers. 17, 721-729 (2012).
27. Zhao, Y. Y. et al. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin. Chim. Acta. 413, 1438-1445 (2012).
28. Schaeffner, E. S. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 14, 2084-2091 (2003).
29. Chen, S. C. et al. Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. PLoS One. 8, e55643 (2013).
30. Iseki, K. et al. Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort. Clin. Exp. Nephrol. 9, 46-52 (2005).
31. Zhao, Y. Y., Vaziri, N. D. & Lin, R. C. Lipidomics: new insight into kidney disease. Adv. Clin. Chem. 68, 153-175 (2015).
32. Martinez-Garcia, C. et al. Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. Dis. Model Mech. 5, 636-648 (2012).
33. Gillett, M. P. et al. Levels of cholesteryl esters and other lipids in the plasma of patients with end-stage renal failure. Ann. Saudi Med. 21, 283-286 (2001).
34. Pradère, J. P. et al. Lysophosphatidic acid and renal fibrosis. BBA-Mol. Cell Biol. L 1781, 582-587 (2008).
35. Moolenaar, W. H., van Meeteren, L. A. & Giepmans, B. N. The ins and outs of lysophosphatidic acid signaling. Bioessays. 26, 870-881 (2004).
36. Heusinger-Ribeiro, J., Eberlein, M., Wahab, N. A. & Goppelt-Struebe, M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J. Am. Soc. Nephrol. 12, 1853-1861 (2001).
37. Arafa, H. M. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology. 254, 51-60 (2008).
38. Matera, M. et al. History of L-carnitine: implications for renal disease. J. Ren. Nutr. 13, 2-14 (2003).
39. Matsumura, M. et al. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron. 72, 574-578 (1996).
40. Giovenali, P. et al. Selective trophic effect of L-carnitine in type I and IIa skeletal muscle fibers. Kidney Int. 46, 1616-1619 (1994).
41. Zeyner, A. & Harmeyer, J. Metabolic functions of L-carnitine and its effects as feed additive in horses. A review. Arch Tierernahr. 52, 115-138 (1999).
42. Adams, G. R. & Vaziri, N. D. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. Am. J. Physiol. Renal Physiol. 290, F753-761 (2006).
43. Yazdi, P. G. et al. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int. J. Clin. Exp. Med. 6, 532-539 (2013).
44. Zambrano, S. et al. L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-gamma. Am. J. Hypertens. 27, 460-470 (2014).
45. Katsoulieris, E. et al. alpha-Linolenic acid protects renal cells against palmitic acid lipotoxicity via inhibition of endoplasmic reticulum stress. Eur. J. Pharmacol. 623, 107-112 (2009).
46. Zhao, Y. Y. et al. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PloS one. 8, e59617 (2013).
47. Hayashi, K. et al. Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1-2 chronic kidney disease. Nephro. Urol. Mon. 3, 164-171 (2011).
48. Yokozawa, T., Zheng, P. D., Oura, H. & Koizumi, F. Animal model of adenine-induced chronic renal failure in rats. Nephron. 44, 230-234 (1986).
49. (E). J. Proteome. Res. 12, 692-703 (2013).
50. Vaziri, N. D. et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PloS one. 9, e114881 (2014).
51. Zhang, Z. H. et al. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Sci. Rep. 5, 14472 (2015).
52. Tofovic, S. P., Dubey, R., Salah, E. M. & Jackson, E. K. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J. Am. Soc. Nephrol. 13, 2737-2747 (2002).
53. Suzuki, Y. et al. Histopathological characterization of renal tubular and interstitial changes in 5/6 nephrectomized marmoset monkeys (Callithrix jacchus). Exp. Toxicol. Pathol. 67, 41-51 (2015).
54. Aminzadeh, M. A. et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 44, 570-578 (2014).
55. Jansson, J. et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One. 4, e6386 (2009).